Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer

NCT01669252 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

163

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Eribulin

Sponsor

SOLTI Breast Cancer Research Group

Collaborators

[object Object]